

REMARKS

Claims 1-29 are pending in this application. Applicants have elected, with traverse, the claims of Group I, claims 1-3, 7-16, and 29, drawn to a combination product comprising an antisense targeted against MBD2 demethylase and an agent used in antitumor chemotherapy for treatment of proliferative and inflammatory diseases.


With regard to the election of species requirement, Applicants hereby elect bleomycin as the anti-tumor agent. With regard to the oligonucleotide, Applicants elect 15 consecutive nucleotides of SEQ ID NO:1, a complimentary sequence or a hybridizing sequence, as set forth in claim 2. This election is for examination purposes only.

Applicants reserve the right to file one or more divisional applications directed to non-elected subject matter. With the entry of this amendment, claims 1-3, 7-16, and 29 will be active in this case. Applicants respectfully request examination of the instant application on the merits in due course.

Respectfully submitted,

Date: August 9, 2006

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036-3001
Telephone: (202) 912-2000
Facsimile: (202) 912-2020



Patricia D. Granados
Attorney for Applicants
Reg. No.: 33,683

Customer No. 26633